keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy and cardiotoxicity

keyword
https://www.readbyqxmd.com/read/27911951/body-surface-area-and-baseline-blood-pressure-predict-subclinical-anthracycline-cardiotoxicity-in-women-treated-for-early-breast-cancer
#1
Paul Kotwinski, Gillian Smith, Jackie Cooper, Julie Sanders, Louise Ma, Albert Teis, David Kotwinski, Michael Mythen, Dudley J Pennell, Alison Jones, Hugh Montgomery
BACKGROUND AND AIMS: Anthracyclines are highly effective chemotherapeutic agents which may cause long-term cardiac damage (chronic anthracycline cardiotoxicity) and heart failure. The pathogenesis of anthracycline cardiotoxicity remains incompletely understood and individual susceptibility difficult to predict. We sought clinical features which might contribute to improved risk assessment. METHODS: Subjects were women with early breast cancer, free of pre-existing cardiac disease...
2016: PloS One
https://www.readbyqxmd.com/read/27910996/speckle-tracking-echocardiography-predicts-early-subclinical-anthracycline-cardiotoxicity-in-patients-with-breast-cancer
#2
Qi Tang, Yan Jiang, Yali Xu, Hongmei Xia
PURPOSE: This study aimed to assess the early changes of left ventricular (LV) and right ventricular (RV) mechanics associated with anthracycline treatment for breast cancer and to determine whether two-dimensional speckle tracking echocardiography (2D-STE) analysis could predict chemotherapy-induced cardiotoxicity. BACKGROUND: Anthracycline generates progressive LV dysfunction associated with a poor prognosis. Early detection of minor change of myocardial mechanics is thus important...
December 2, 2016: Journal of Clinical Ultrasound: JCU
https://www.readbyqxmd.com/read/27909727/anti%C3%A2-proliferative-activity-of-epigallocatechin%C3%A2-3%C3%A2-gallate-and-silibinin-on-soft-tissue-sarcoma-cells
#3
Kamran Harati, Björn Behr, Christoph Wallner, Adrien Daigeler, Tobias Hirsch, Frank Jacobsen, Marcus Renner, Ali Harati, Marcus Lehnhardt, Mustafa Becerikli
Disseminated soft tissue sarcomas (STS) present a therapeutic dilemma. The first-line cytostatic doxorubicin demonstrates a response rate of 30% and is not suitable for elderly patients with underlying cardiac disease, due to its cardiotoxicity. Well‑tolerated alternative treatment options, particularly in palliative situations, are rare. Therefore, the present study assessed the anti‑proliferative effects of the natural compounds epigallocatechin-3-gallate (EGCG), silibinin and noscapine on STS cells. A total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS‑402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197)...
November 28, 2016: Molecular Medicine Reports
https://www.readbyqxmd.com/read/27903214/chemotherapy-and-cardiotoxicity-in-hematologic-malignancies-a-review
#4
Antonio Stellitano, Roberta Fedele, Santina Barillà, Antonino Iaria, Carmelo Massimiliano Rao, Massimo Martino
Antineoplastic agents affect the cardiovascular system, and the incidence of cardiotoxicity is continuously growing in patients with hematologic malignancies and treated with antineoplastic therapy. Cardio-oncology is a quite young discipline, designed for diagnosis, prevention and treatment of cardiovascular complications of anticancer agents. Nowadays, with the current treatments and an accurate pharmacological control of comorbidities present at the time of the oncological diagnosis, early clinical events are infrequent, and it seems indeed that cardiotoxicity could emerge as time and years go by, after therapies completion...
November 21, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27902477/astragalus-polysaccharide-restores-autophagic-flux-and-improves-cardiomyocyte-function-in-doxorubicin-induced-cardiotoxicity
#5
Yuan Cao, Tao Shen, Xiuqing Huang, Yajun Lin, Beidong Chen, Jing Pang, Guoping Li, Que Wang, Sylvia Zohrabian, Chao Duan, Yang Ruan, Yong Man, Shu Wang, Jian Li
Doxorubicin (adriamycin), an anthracycline antibiotic, is commonly used to treat many types of solid and hematological malignancies. Unfortunately, clinical usage of doxorubicin is limited due to the associated acute and chronic cardiotoxicity. Previous studies demonstrated that Astragalus polysaccharide (APS), the extracts of Astragalus membranaceus, had strong anti-tumor activities and anti-inflammatory effects. However, whether APS could mitigate chemotherapy-induced cardiotoxicity is unclear thus far. We used a doxorubicin-induced neonatal rat cardiomyocyte injury model and a mouse heart failure model to explore the function of APS...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27889760/pamidronate-attenuates-oxidative-stress-and-energetic-metabolism-changes-but-worsens-functional-outcomes-in-acute-doxorubicin-induced-cardiotoxicity-in-rats
#6
Paula Bernardo de Carvalho, Andréa de Freitas Gonçalves, Patrícia Helena Correa Alegre, Paula Schmidt Azevedo, Meliza Goi Roscani, Carolina Marabesi Bergamasco, Pamela N Modesto, Ana Angélica Fernandes, Marcos Ferreira Minicucci, Sergio Alberto Rupp Paiva, Leonardo Antonio, Mamede Zornoff, Bertha Furlan Polegato
BACKGROUND: Cardiotoxicity is the major side effect of doxorubicin. As mechanisms that are involved in cardiotoxicity are ambiguous, new methods for attenuating cardiotoxicity are needed. Recent studies have shown that bisphosphonates can decrease oxidative stress. Therefore, the objective of this study was to evaluate the effect of pamidronate on preventing acute doxorubicin-induced cardiotoxicity. METHODS: Sixty-four male Wistar rats were allocated into four groups: the control group (C), the pamidronate group (P), the doxorubicin group (D) and the doxorubicin/pamidronate group (DP)...
November 25, 2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27883296/adjuvant-trastuzumab-a-10-year-overview-of-its-benefit
#7
Matteo Lambertini, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja
Anti-HER2 targeted therapy is one of the key advances in the treatment of breast cancer that have occurred in the last 20 years. In the adjuvant setting, the use of trastuzumab has led to prolonged and sustained survival benefit with very little toxicity as also confirmed by the 10-year follow-up results from the pivotal trials. Despite the survival improvement, several key issues are not entirely resolved in this field. These issues have led to multiple research efforts in de-escalating or escalating the standard treatment with chemotherapy and 1 year of adjuvant trastuzumab...
November 24, 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27881009/late-cardiac-effect-of-anthracycline-therapy-in-physically-active-breast-cancer-survivors-a-prospective-study
#8
A C Nagy, P GulAcsi-BArdos, Z CserEp, L Hangody, T Forster
The late-onset cardiotoxic effect of anthracycline is known, however the early detection and prevention of subclinical myocardial damage has not been fully understood yet. Besides medical therapy regular physical activities may also play a role in the prevention and reduction of side effects of chemotherapy. The aim of our present study was to detect the effect of regular physical activities on the diastolic function and on the symptoms of late heart failure in case of anthracycline chemotherapy. The prospective study included 55 female patients (age 31-65 year, average 49...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27878803/tissue-doppler-echocardiography-detects-subclinical-left-ventricular-dysfunction-in-patients-undergoing-chemotherapy-for-colon-cancer-insights-from-oncoecho-multicenter-study
#9
Edyta Płońska-Gościniak, Monika Różewicz, Jarosław Kasprzak, Andrzej Wojtarowicz, Katarzyna Mizia-Stec, Tomasz Hryniewiecki, Piotr Pysz, Andrzej Kułach, Artur Bodys, Violetta Sulżyc, Wojciech Braksator, Andrzej Szyszka, Beata Zaborska, Adrianna Gościńska-Szmagała, Maciej Siński, Dariusz Kosior, Ilona Kowalik, Zbigniew Gąsior
I BACKGROUND: Colorectal cancer (CRC) is the second most common cancer in women and the third in men in Poland. The role of chemotherapy (CTX) depends on stage of CRC: adjuvant CTX is a standard treatment in stage III and should also be considered in stage II with risk factors. AIM: The aim of the paper was to assess the cardiovascular consequences of CTX in CRC enrolled to the ONCOECHO multicenter study (2012 - 2014). To identify potential cardiotoxicity we focused on myocardial function, heart rhythm and conduction disorders and adverse cardiovascular events...
November 23, 2016: Kardiologia Polska
https://www.readbyqxmd.com/read/27866063/anticancer-therapy-induced-vascular-toxicity-vegf-inhibition-and-beyond
#10
REVIEW
Daniela Di Lisi, Rosalinda Madonna, Concetta Zito, Enrico Bronte, Giuseppe Badalamenti, Paolo Parrella, Ines Monte, Carlo Gabriele Tocchetti, Antonio Russo, Giuseppina Novo
Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemotherapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT interval prolongation and arrhythmias. Currently, a field of intense research is the vascular toxicity induced by new biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) and other tyrosine kinases...
November 9, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27862675/the-physiotherapist-and-the-esophageal-cancer-patient-from-prehabilitation-to-rehabilitation
#11
REVIEW
E M Guinan, J Dowds, C Donohoe, J V Reynolds, J Hussey
Esophageal cancer is a serious malignancy often treated with multimodal interventions and complex surgical resection. As treatment moves to centers of excellence with emphasis on enhanced recovery approaches, the role of the physiotherapist has expanded. The aim of this review is to discuss the rationale behind both the evolving prehabilitative role of the physiotherapist and more established postoperative interventions for patients with esophageal cancer. While a weak association between preoperative cardiopulmonary fitness and post-esophagectomy outcome is reported, cardiotoxicity during neoadjuvant chemotherapy and/or radiotherapy may heighten postoperative risk...
November 9, 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/27858859/risk-factors-of-trastuzumab-induced-cardiotoxicity-in-breast-cancer-a-meta-analysis
#12
Zeeshan Jawa, Ruth M Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K Khandheria, Arshad Jahangir, Yang Shi
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of patients treated with trastuzumab will develop heart failure and ∼10% will experience a reduction in left ventricular ejection fraction (LVEF), the patient risk factors associated with trastuzumab-induced cardiotoxicity (TIC) are unclear...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27852680/successful-recovery-and-allogeneic-stem-cell-transplant-following-chemotherapy-induced-severe-cardiomyopathy-literature-review-of-management-and-prognostic-factors
#13
Muhammad Asim Shahzad, Rizwan Ishtiaq, Umar Zahid, Faiz Anwer
Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential...
November 16, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27843627/twenty-years-of-anti-her2-therapy-associated-cardiotoxicity
#14
REVIEW
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja
Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3 trial of trastuzumab, 27% of patients receiving anthracyclines and trastuzumab experienced cardiac events and 16% suffered from severe congestive heart failure. In subsequent trials conducted in advanced and early settings, the incidence of cardiac events was reduced through changes in chemotherapy regimens, more strict patient selection and close cardiac assessment...
2016: ESMO Open
https://www.readbyqxmd.com/read/27842711/-radiation-related-heart-toxicity-update-in-women
#15
S Marlière, E Vautrin, C Saunier, A Chaikh, I Gabelle-Flandin
Breast cancer is a common diagnosis in women and thus women are at risk of radiation-induced heart disease, in particular during radiotherapy for left breast cancer and when the internal mammary chain is included. Rates of major cardiac events increase with younger age at the time of irradiation, diagnosis before 1990s, higher radiation doses, coexisting cardiovascular risk factors and adjuvant cardiotoxic chemotherapy. Radiation-induced heart disease comprises a spectrum of cardiac pathologies, including pericardial disease, cardiomyopathy, coronary artery disease and valvular disease...
December 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/27830273/-summary-of-the-esc-position-paper-on-cancer-treatment-and-cardiovascular-toxicity
#16
J Hoog, S Achenbach
The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension...
December 2016: Herz
https://www.readbyqxmd.com/read/27829985/potential-therapeutic-strategies-for-hypertension-exacerbated-cardiotoxicity-of-anticancer-drugs
#17
REVIEW
Robin K Kuriakose, Rakesh C Kukreja, Lei Xi
Despite their recognized cardiotoxic effects, anthracyclines remain an essential component in many anticancer regimens due to their superior antitumor efficacy. Epidemiologic data revealed that about one-third of cancer patients have hypertension, which is the most common comorbidity in cancer registries. The purpose of this review is to assess whether anthracycline chemotherapy exacerbates cardiotoxicity in patients with hypertension. A link between hypertension comorbidity and anthracycline-induced cardiotoxicity (AIC) was first suggested in 1979...
2016: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/27816693/are-cardioprotective-effects-of-no-releasing-drug-molsidomine-translatable-to-chronic-anthracycline-cardiotoxicity-settings
#18
Olga Lenčová-Popelová, Hana Jansová, Eduard Jirkovský, Jan Bureš, Anna Jirkovská-Vávrová, Yvona Mazurová, Petra Reimerová, Lucie Vostatková, Michaela Adamcová, Miloš Hroch, Zuzana Pokorná, Petra Kovaříková, Tomáš Šimůnek, Martin Štěrba
Chronic anthracycline (ANT) cardiotoxicity is a serious complication of cancer chemotherapy. Molsidomine, a NO-releasing drug, has been found cardioprotective in different models of I/R injury and recently in acute high-dose ANT cardiotoxicity. Hence, we examined whether its cardioprotective effects are translatable to chronic ANT cardiotoxicity settings without induction of nitrosative stress and interference with antiproliferative action of ANTs. The effects of molsidomine (0.025 and 0.5mg/kg, i.v.) were studied on the well-established model of chronic ANT cardiotoxicity in rabbits (daunorubicin/DAU/3mg/kg/week for 10 weeks)...
November 30, 2016: Toxicology
https://www.readbyqxmd.com/read/27800661/incidence-time-of-occurrence-and-response-to-heart-failure-therapy-in-patients-with-anthracycline-cardiotoxicity
#19
Arshad A Khan, Asma Ashraf, Rajinder Singh, Adil Rahim, Walid Rostom, Mumtaz Hussain, Ian Renner, Nicholas J Collins
BACKGROUND: Anthracyclines are commonly used chemotherapeutic medications. In the current analysis we evaluated all-cause mortality and incidence, timing and response to medical therapy of anthracycline cardiotoxicity. METHODS: Left ventricular ejection fraction (LVEF) was serially assessed using gated heart pool scan/echocardiography in patients receiving anthracycline based chemotherapy from January 2009 to December 2014. RESULTS: A total of 1204 patients were administered anthracyclines during the study period...
November 1, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27799559/vegf-b-gene-therapy-inhibits-doxorubicin-induced-cardiotoxicity-by-endothelial-protection
#20
Markus Räsänen, Joni Degerman, Tuuli A Nissinen, Ilkka Miinalainen, Risto Kerkelä, Antti Siltanen, Janne T Backman, Eero Mervaala, Juha J Hulmi, Riikka Kivelä, Kari Alitalo
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity and congestive heart failure...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
keyword
keyword
83280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"